Britain first to approve AstraZeneca/Oxford COVID-19 vaccine | Inquirer News

Britain first to approve AstraZeneca/Oxford COVID-19 vaccine

/ 03:31 PM December 30, 2020

FILE PHOTO: Vials with a sticker reading, “COVID-19 / Coronavirus vaccine / Injection only” and a medical syringe are seen in front of a displayed AstraZeneca logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

LONDON — Britain on Wednesday became the first country in the world to approve a coronavirus vaccine developed by Oxford University and AstraZeneca as it battles a major winter surge driven by a new, highly contagious variant of the virus.

AstraZeneca said the authorization was for a two-dose regime, and that the vaccine had been approved for use for emergency supply. Britain has ordered 100 million doses of the vaccine.

Article continues after this advertisement

“The government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorize Oxford University/AstraZeneca’s COVID-19 vaccine for use,” the health ministry said.

FEATURED STORIES

The pandemic has already killed 1.7 million people around the world, sown chaos through the global economy, and upended normal life for billions since it began in Wuhan, China, a year ago.

Britain and South Africa in particular are grappling with new variants of the coronavirus, which the government and scientists say are more contagious; many countries have responded by banning passenger flights and blocking trade.

Article continues after this advertisement

AstraZeneca and other developers have said they are studying the impact of the new variant but expect that their shots will be effective against it.

Article continues after this advertisement

The regulatory endorsement is a welcome boost for AstraZeneca and the Oxford team, which have been accused of a lack of clarity about the results from late-stage trials.

Article continues after this advertisement

Pooled results from those trials show it had overall efficacy was 70.4%. Efficacy was 62% for trial participants given two full doses, but 90% for a smaller sub-group given a half, then a full dose.

Researchers said that the finding of 90% efficacy for the low-dose/high-dose regime needed more investigation. AstraZeneca did not specify which dose regime had been approved.

Article continues after this advertisement

“Today is an important day for millions of people in the UK who will get access to this new vaccine,” AstraZeneca Chief Executive Pascal Soriot said.

“It has been shown to be effective, well-tolerated, simple to administer, and is supplied by AstraZeneca at no profit.”

/MUF
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: AstraZeneca, Britain, COVID-19, vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.